Back
Hepatitis C 
Hepatitis C Topics HCV Treatment
Hepatitis C Topics HCV Treatment
HCV Treatment
New HCV NS5A Inhibitor ACH-3102 Enters Clinical Trials, Gets FDA Fast-Track Status
- Details
- Category: HCV Treatment
- Published on Wednesday, 16 May 2012 00:00
- Written by Press Release
Achillion's second-generation hepatitis C virus (HCV) NS5A inhibitor ACH-3102 is now undergoing Phase 1 clinical testing and has been granted "Fast Track" status, a U.S. Food and Drug Administration designation for experimental therapies that address urgent unmet need, the company announced this week.
